Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Schizophrenia
July 28, 2025
Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical